Buzzard Pharmaceuticals is developing Isunakinra, a potent inhibitor of interleukin-1 alpha and beta signaling. IL-1 is produced by tumor cells and macrophages, leading to increased tumor immunosuppression (MDSCs and M2 macrophages), angiogenesis and metastasis. A phase I/II trial in solid tumor patients will start soon at Baylor (Dallas) where we will assess effects on downstream biomarkers IL-6 and CRP as well as effects on patient tumors in combination with a PD-1 inhibitor.